Splash Beverage Enters Exclusive Global Licensing Agreement with Argent BioPharma for CannEpil
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 20 hours ago
0mins
Splash Beverage announced that it has entered into an exclusive global licensing agreement with Argent BioPharma for CannEpil, a proprietary, patent protected cannabinoid-based investigational therapeutic approved for the treatment of drug-resistant epilepsy in multiple European countries. As part of the transaction, Splash has secured a $1M strategic investment commitment from C/M Capital Partners to support regulatory advancement, clinical development planning, commercialization initiatives and strategic partnership activities. Splash intends to deploy proceeds from the strategic investment toward advancing FDA-related activities, expanding the existing clinical and real-world evidence package, engaging U.S. epilepsy investigators and identifying a strategic pharmaceutical development partner capable of supporting future U.S.-based clinical trials. Under the terms of the agreement, Splash has acquired exclusive worldwide rights to develop, commercialize, market, distribute, sublicense and sell CannEpil for the treatment of drug-resistant epilepsy, refractory epilepsy, seizure disorders and related neurological conditions. The license encompasses all global territories and includes rights to future product improvements, reformulations and next-generation product developments within the licensed field. In addition to its affiliate's $1M capital infusion described above and as consideration for the transaction, Mercer Street Global Opportunity Fund agreed to forgive approximately $5M of Argent BioPharma indebtedness and Splash agreed to issue to $5.5M of newly issued Splash preferred equity as part of the consideration for the license, aligning stakeholders behind the future development and commercialization of the CannEpil platform. Argent BioPharma is incentivized to continue to participate in the long-term success of the program through a royalty equal to 15% of net revenue generated from worldwide sales of CannEpil. The agreement grants Splash exclusive worldwide commercialization rights for an initial twenty-year term and includes rights to sublicense the technology to strategic pharmaceutical partners
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SBEV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SBEV
About SBEV
Splash Beverage Group, Inc. seeks to identify, acquire, and build early stage or under-valued beverage brands that have growth potential within its distribution system. The Company’s distribution system is comprehensive in the United States and is expanding to select international markets. Through its division Qplash, Splash’s distribution reach includes e-commerce access to both business-to-business (B2B) and business-to-consumer (B2C) customers. It markets beverage brands to customers throughout the United States that prefer delivery direct to their office, facilities, or homes. Its segments include Splash Beverage Group and E-Commerce. The Company's Splash Beverage Group segment includes the manufacture and distribution of non-alcoholic and alcoholic branded beverages. The E-commerce segment is engaged in the sale of e-commerce beverages. Its brands include Copa di Vino single-serve wine, Pulpoloco Sangria, SALT Tequila, and Chispo Tequila.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Splash Beverage Secures Exclusive Global License for CannEpil
- Exclusive Global License: Splash Beverage Group has entered into an exclusive global licensing agreement with Argent BioPharma for CannEpil, which is expected to significantly enhance the company's market share in neurology by addressing the needs of approximately 30% of drug-resistant epilepsy patients worldwide.
- Strategic Investment Support: C/M Capital Partners has committed to invest $1 million in Splash to support the clinical development and commercialization of CannEpil in the U.S., indicating strong market confidence and potential revenue growth opportunities for the product.
- International Market Access: CannEpil has been approved in multiple countries including Ireland, the UK, Germany, and Australia, adhering to EU-GMP standards, which lays a solid foundation for Splash's expansion into international markets.
- Long-Term Revenue Potential: The agreement grants Splash exclusive commercialization rights for CannEpil for an initial term of 20 years, along with a 15% royalty on global net sales, ensuring a long-term partnership with Argent BioPharma that will drive future product development and market growth.
See More
Splash Beverage Enters Exclusive Licensing Agreement with Argent BioPharma for CannEpil
- Exclusive Global Licensing Agreement: Splash Beverage Group has entered into an exclusive global licensing agreement with Argent BioPharma for CannEpil, a proprietary treatment for drug-resistant epilepsy, which is expected to significantly enhance the company's competitive position in the global pharmaceutical market.
- Strategic Investment Support: Splash has secured a $1 million strategic investment commitment from C/M Capital Partners to accelerate CannEpil's regulatory advancement and clinical development in the U.S. and other key markets, further strengthening its market position.
- Debt Forgiveness and Equity Issuance: Mercer Street Global Opportunity Fund agreed to forgive approximately $5 million of Argent BioPharma's debt, while Splash will issue $5.5 million in newly issued preferred equity to support the future development and commercialization of CannEpil, aligning stakeholder interests.
- Long-Term Commercialization Rights: The agreement grants Splash exclusive worldwide commercialization rights for an initial twenty-year term, including rights to sublicense the technology to strategic pharmaceutical partners globally, indicating the company's strong commitment to future product improvements and market expansion.
See More
Splash Secures $1 Million Investment for CannEpil Advancement
- Investment Commitment: Splash Beverage Group has secured a $1 million investment commitment from C/M Capital Partners to support regulatory advancement, clinical development planning, and commercialization initiatives for CannEpil, aiming to accelerate its development in the U.S. and other markets.
- Equity Issuance: In addition to the investment commitment, Splash has agreed to issue $5.5 million of newly issued preferred equity, which will bolster the company's capital structure and provide funding for future growth opportunities.
- Global Licensing Agreement: Splash has entered into an exclusive global licensing agreement with Argent BioPharma, granting it 20 years of worldwide commercialization rights for CannEpil, which is expected to create significant revenue potential in the drug-resistant epilepsy market.
- Market Reaction: Despite Splash's stock dropping over 35% in pre-market trading on Tuesday, retail sentiment shifted from 'Bearish' to 'Extremely Bullish', indicating optimism about CannEpil's future prospects.
See More
Splash Beverage Enters Exclusive Global Licensing Agreement for CannEpil with Argent BioPharma
- Exclusive Global Licensing Agreement: Splash Beverage has entered into an exclusive global licensing agreement with Argent BioPharma for CannEpil®, gaining rights to develop and commercialize this cannabinoid-based treatment, which addresses the significant unmet needs of the 30% of epilepsy patients resistant to current therapies.
- Strategic Investment Support: C/M Capital Partners has committed $1 million in strategic investment to support the regulatory advancement and clinical development of CannEpil in the U.S., enhancing Splash's competitive position in the global market.
- International Market Access: CannEpil has been approved in multiple international markets, including Ireland, the UK, Germany, and Australia, becoming a crucial option for drug-resistant epilepsy treatment, and is expected to drive revenue growth through existing international commercialization channels.
- Long-Term Revenue Potential: The agreement grants Splash exclusive commercialization rights for 20 years, including rights to future product improvements, with a 15% net revenue royalty incentivizing Argent BioPharma's participation in the program's long-term success.
See More
Splash Beverage Completes Strategic Investment in Avicanna
- Strategic Investment Completed: Splash Beverage Group has finalized a CDN$300,000 investment in Avicanna Inc., aimed at advancing its transformation into a cannabinoid health and biopharmaceutical platform, thereby enhancing its competitive position in the market.
- Market Positioning Advantage: Avicanna is recognized as one of North America's leading cannabinoid-based biopharmaceutical companies, possessing proprietary formulations and clinical-stage pharmaceutical assets that uniquely position it for the evolving medical cannabinoid market in the U.S.
- Diverse Product Portfolio: Avicanna's portfolio includes Trunerox™, an approved cannabidiol treatment for severe epilepsy, along with multiple clinical development programs targeting pain, inflammation, and dermatological conditions, showcasing its broad application potential in the medical field.
- Strong Management Team: Avicanna boasts an experienced management team with deep expertise in healthcare, pharmaceuticals, and clinical research, coupled with a debt-free balance sheet, establishing a solid foundation for future growth.
See More
Splash Beverage Submits Compliance Plan to NYSE American
- Compliance Plan Submission: Splash Beverage Group announced on Wednesday that it submitted a compliance plan to NYSE American to address listing deficiencies, filed on May 28, aimed at restoring compliance and ensuring the company's continued listing eligibility.
- Potential Cure Period: If accepted, the plan could grant Splash Beverage a cure period extending through January 29, 2027, allowing the company time to implement necessary corrective actions, thereby improving its financial standing and restoring investor confidence.
- Stock Price Volatility: Shares of Splash Beverage have lost 42% in the last month, reflecting market concerns over its compliance issues, yet the stock rose 4% in premarket trading following the compliance plan submission, indicating cautious optimism among investors regarding the company's future.
- Management Statement: The interim CEO stated that the submission of the compliance plan represents an important milestone, demonstrating the company's proactive measures to meet NYSE listing standards, which enhances market confidence in its ability to restore compliance.
See More
Splash Beverage Secures Exclusive Global License for CannEpil
- Exclusive Global License: Splash Beverage Group has entered into an exclusive global licensing agreement with Argent BioPharma for CannEpil, which is expected to significantly enhance the company's market share in neurology by addressing the needs of approximately 30% of drug-resistant epilepsy patients worldwide.
- Strategic Investment Support: C/M Capital Partners has committed to invest $1 million in Splash to support the clinical development and commercialization of CannEpil in the U.S., indicating strong market confidence and potential revenue growth opportunities for the product.
- International Market Access: CannEpil has been approved in multiple countries including Ireland, the UK, Germany, and Australia, adhering to EU-GMP standards, which lays a solid foundation for Splash's expansion into international markets.
- Long-Term Revenue Potential: The agreement grants Splash exclusive commercialization rights for CannEpil for an initial term of 20 years, along with a 15% royalty on global net sales, ensuring a long-term partnership with Argent BioPharma that will drive future product development and market growth.
See More
Splash Beverage Enters Exclusive Licensing Agreement with Argent BioPharma for CannEpil
- Exclusive Global Licensing Agreement: Splash Beverage Group has entered into an exclusive global licensing agreement with Argent BioPharma for CannEpil, a proprietary treatment for drug-resistant epilepsy, which is expected to significantly enhance the company's competitive position in the global pharmaceutical market.
- Strategic Investment Support: Splash has secured a $1 million strategic investment commitment from C/M Capital Partners to accelerate CannEpil's regulatory advancement and clinical development in the U.S. and other key markets, further strengthening its market position.
- Debt Forgiveness and Equity Issuance: Mercer Street Global Opportunity Fund agreed to forgive approximately $5 million of Argent BioPharma's debt, while Splash will issue $5.5 million in newly issued preferred equity to support the future development and commercialization of CannEpil, aligning stakeholder interests.
- Long-Term Commercialization Rights: The agreement grants Splash exclusive worldwide commercialization rights for an initial twenty-year term, including rights to sublicense the technology to strategic pharmaceutical partners globally, indicating the company's strong commitment to future product improvements and market expansion.
See More
Splash Secures $1 Million Investment for CannEpil Advancement
- Investment Commitment: Splash Beverage Group has secured a $1 million investment commitment from C/M Capital Partners to support regulatory advancement, clinical development planning, and commercialization initiatives for CannEpil, aiming to accelerate its development in the U.S. and other markets.
- Equity Issuance: In addition to the investment commitment, Splash has agreed to issue $5.5 million of newly issued preferred equity, which will bolster the company's capital structure and provide funding for future growth opportunities.
- Global Licensing Agreement: Splash has entered into an exclusive global licensing agreement with Argent BioPharma, granting it 20 years of worldwide commercialization rights for CannEpil, which is expected to create significant revenue potential in the drug-resistant epilepsy market.
- Market Reaction: Despite Splash's stock dropping over 35% in pre-market trading on Tuesday, retail sentiment shifted from 'Bearish' to 'Extremely Bullish', indicating optimism about CannEpil's future prospects.
See More
Splash Beverage Enters Exclusive Global Licensing Agreement for CannEpil with Argent BioPharma
- Exclusive Global Licensing Agreement: Splash Beverage has entered into an exclusive global licensing agreement with Argent BioPharma for CannEpil®, gaining rights to develop and commercialize this cannabinoid-based treatment, which addresses the significant unmet needs of the 30% of epilepsy patients resistant to current therapies.
- Strategic Investment Support: C/M Capital Partners has committed $1 million in strategic investment to support the regulatory advancement and clinical development of CannEpil in the U.S., enhancing Splash's competitive position in the global market.
- International Market Access: CannEpil has been approved in multiple international markets, including Ireland, the UK, Germany, and Australia, becoming a crucial option for drug-resistant epilepsy treatment, and is expected to drive revenue growth through existing international commercialization channels.
- Long-Term Revenue Potential: The agreement grants Splash exclusive commercialization rights for 20 years, including rights to future product improvements, with a 15% net revenue royalty incentivizing Argent BioPharma's participation in the program's long-term success.
See More
Splash Beverage Completes Strategic Investment in Avicanna
- Strategic Investment Completed: Splash Beverage Group has finalized a CDN$300,000 investment in Avicanna Inc., aimed at advancing its transformation into a cannabinoid health and biopharmaceutical platform, thereby enhancing its competitive position in the market.
- Market Positioning Advantage: Avicanna is recognized as one of North America's leading cannabinoid-based biopharmaceutical companies, possessing proprietary formulations and clinical-stage pharmaceutical assets that uniquely position it for the evolving medical cannabinoid market in the U.S.
- Diverse Product Portfolio: Avicanna's portfolio includes Trunerox™, an approved cannabidiol treatment for severe epilepsy, along with multiple clinical development programs targeting pain, inflammation, and dermatological conditions, showcasing its broad application potential in the medical field.
- Strong Management Team: Avicanna boasts an experienced management team with deep expertise in healthcare, pharmaceuticals, and clinical research, coupled with a debt-free balance sheet, establishing a solid foundation for future growth.
See More
Splash Beverage Submits Compliance Plan to NYSE American
- Compliance Plan Submission: Splash Beverage Group announced on Wednesday that it submitted a compliance plan to NYSE American to address listing deficiencies, filed on May 28, aimed at restoring compliance and ensuring the company's continued listing eligibility.
- Potential Cure Period: If accepted, the plan could grant Splash Beverage a cure period extending through January 29, 2027, allowing the company time to implement necessary corrective actions, thereby improving its financial standing and restoring investor confidence.
- Stock Price Volatility: Shares of Splash Beverage have lost 42% in the last month, reflecting market concerns over its compliance issues, yet the stock rose 4% in premarket trading following the compliance plan submission, indicating cautious optimism among investors regarding the company's future.
- Management Statement: The interim CEO stated that the submission of the compliance plan represents an important milestone, demonstrating the company's proactive measures to meet NYSE listing standards, which enhances market confidence in its ability to restore compliance.
See More
